Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Botanix Pharmaceuticals Limited ( (AU:BOT) ) has provided an announcement.
Botanix Pharmaceuticals Limited has issued 200,000 new fully paid ordinary shares following the exercise of unquoted options. This move, compliant with the Corporations Act, allows the shares to be traded immediately, enhancing the company’s market liquidity and potentially attracting more investors.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$0.27 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a dermatology company based in Philadelphia and Phoenix, specializing in innovative treatments for skin conditions. The company has received FDA approval for Sofdra™, a novel treatment for primary axillary hyperhidrosis, marking it as the first new chemical entity approved for this condition.
Average Trading Volume: 15,090,331
Technical Sentiment Signal: Sell
Current Market Cap: A$284.4M
See more data about BOT stock on TipRanks’ Stock Analysis page.